CD274 and breast carcinoma: Based on these findings, we initiated a multicenter prospective randomized controlled trial to explore the effectiveness and safety of anti‐PD‐L1 treatment combined with chemotherapy compared with chemotherapy alone in TNBC patients (NCT06229067) and prospectively collected patient tissue and blood samples for translational research to further elucidate these biomarkers indicative of immunotherapeutic response in advanced breast cancer.